Coverage
— → Added to coverage
Current stock research snapshot · Not reviewed Date unavailable
BNTXBioNTech
Investment conviction●●●○○3 of 5 · current snapshot
Research target—Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$25.64BSnapshot value · Not reviewed
Research history
See all BNTX changes ↗What changed
Broadest mRNA oncology platform: personalized autogene cevumeran (BNT122, partnered Roche/Genentech) + shared-antigen + checkpoint combinations. Efficacy proof earlier than Moderna (pancreatic Ph1 signal), platform broader, cash-rich. Demand engine feeding Read (tumor sequencing) + Manufacture toll-roads.
BNT122 pancreatic/CRC/melanoma Phase 2 readouts; Roche partnership milestones; platform cash deployment into combination trials.
autogene cevumeran misses in randomized trials; Moderna/MRK establish unbeatable personalized lead; platform does not translate to durable economics.
No social-sentiment snapshot available.
Snapshot · Not reviewed🟡 Mixed · ins-$5.5M · 13F 11+/9-×0.5 · short↑0.21
Snapshot · Not reviewed